Menistin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Menistin

Property Description
Active Ingredient Betahistine
Form Oral tablets
Pharmacological Class Histamine analogue; Antivertigo agent
General Purpose To stabilize the vestibular system and relieve vertigo
Origin Synthetic

Menistin is a medicinal product containing the active substance Betahistine, a synthetic histamine analogue classified as an antivertigo agent. This medication is clinically recognized for its role in helping to manage severe balance disruption and persistent spinning sensations, typically utilized in adult patient groups.


What Type of Medicine is Menistin?

Menistin is administered in the form of an oral tablet and is a single-ingredient product featuring Betahistine. This active ingredient is chemically similar to the body's natural signaling molecule, histamine, enabling targeted action. The synthetic origin allows for predictable formulation and consistent delivery.

The pharmacological class designation as an antivertigo agent indicates its specific focus on stabilizing the vestibular system, the complex network in the inner ear responsible for maintaining balance. The medicine is classified under the Anatomical Therapeutic Chemical (ATC) code N07CA01.


Betahistine: Composition and High-Level Function

The core component of Menistin is the active ingredient Betahistine (typically present as the dihydrochloride or hydrochloride salt), contained within a solid pharmaceutical base forming the tablet. The general function of Betahistine is to support the body’s own compensatory processes by modulating certain histamine receptors, which influences local blood flow in the inner ear and alters nerve signaling in the brain's balance centers.

Clinical research indicates an overall efficacy for Betahistine in reducing vertigo symptoms compared to placebo, providing general therapeutic support for patients experiencing balance disturbances.


General Therapeutic Role of the Antivertigo Agent

The overall role of this antivertigo agent is to help stabilize the vestibular system and alleviate symptoms related to severe motion and balance disruption. By supporting equilibrium and reducing nerve activity related to imbalance, the medicine's general purpose is to provide relief from persistent sensations of dizziness and spinning, known as vertigo. Its use is foundational in addressing the underlying balance deficit.

What side effects are possible with Menistin?

Possible Side Effects and Safety Information

The safety profile of Menistin (Betahistine) is documented through clinical trial data and post-marketing surveillance reports, categorized by frequency and the body system affected. All safety information is based on official government regulatory documents.


Adverse Reactions and Frequencies

Adverse effects are formally classified according to their estimated incidence:

Classification Adverse Reactions
Common (ge 1/100 to <1/10) Headache, Nausea, Dyspepsia (Indigestion)
Frequency Not Known Thrombocytopenia, Hypersensitivity reactions (including anaphylaxis), mild gastrointestinal complaints (e.g., vomiting, abdominal pain), and cutaneous reactions (e.g., urticaria, rash).

These effects are grouped into System-Organ Classes, primarily involving Nervous System Disorders (Headache), Gastrointestinal Disorders, and Immune/Skin Systems (Hypersensitivity events).


Regulatory Safety Constraints and Precautions

Official prescribing information outlines specific situations where the medicine should not be used or requires careful monitoring:

  • Contraindications: Menistin is formally contraindicated in patients with Phaeochromocytoma due to the risk of inducing severe hypertension, and in individuals with known hypersensitivity to the active substance.

  • Special Precautions: Caution is advised, and monitoring may be necessary, for patients with bronchial asthma, a history of peptic ulceration, and individuals experiencing severe hypotension.

  • Serious Adverse Reactions: The potential for severe Hypersensitivity reactions, such as Anaphylaxis, is officially documented among the post-marketing reports.


Population-Specific Statements

Regulatory safety statements specify that use is not recommended for the paediatric population (under 18 years) due to insufficient data on safety and efficacy in this age group. Post-marketing experience suggests that no dose adjustment is typically necessary for older adults or individuals with hepatic or renal impairment.

Overdose and Emergency Response

Overdose involving Menistin (Betahistine) is officially documented to present primarily with gastrointestinal and central nervous system effects. Symptoms observed in cases of overdose, including those up to 640 mg of the active substance, commonly include nausea, vomiting, abdominal pain, dyspepsia, dry mouth, somnolence (drowsiness), and ataxia (loss of coordination).

More serious complications are associated with very high or intentional overdose. These severe outcomes may include convulsions (seizures), pulmonary complications, and cardiac complications. Regulatory information specifically notes that the risk of these life-threatening events is increased when Menistin is taken in combination with other overdosed drugs.

Immediate medical attention is required if an overdose is suspected; regulatory guidelines mandate that a patient must go to a hospital immediately. Overdose management is limited to symptomatic treatment and general supportive measures, as official labeling confirms that no specific antidote is known. Medical professionals may consider procedural steps such as gastric lavage within one hour of intake. The entire overdose profile dictates that the necessary actions are focused on rapid, professional supportive care.

Therapeutic Uses of Menistin

Menistin is commonly used in conditions characterized by periods of heightened symptoms, such as Ménière's disease and other inner-ear disorders causing vertigo. The medicine is utilized across domains where additional symptomatic support is needed to address the pronounced symptoms related to systemic imbalance, including the sensation of spinning and unsteadiness.

The medicine is considered relevant when supportive symptom management is appropriate for conditions involving recurrent or episodic manifestations. It is applied in clinical settings that involve acute or unstable symptom patterns, which is relevant for easing the core spinning sensation, associated tinnitus (ringing), and feelings of aural fullness. This therapeutic approach may assist with maintaining a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes. Its use is generally associated with improved comfort during symptomatic periods and helps patients cope more steadily.

“Menistin is relevant for easing symptom clusters that may become intense or disruptive, such as vertigo and the nausea that often accompanies it.”

Quick Fact: Supportive Management for Symptoms of Vertigo and Tinnitus

Menistin is used in situations involving certain distressing symptoms that interfere with daily comfort. It is applied when patients experience pronounced nausea and vomiting alongside acute balance issues, providing supportive relief when these disruptive symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Menistin?

The population eligibility for Menistin (Betahistine) is strictly defined by regulatory documents, which establish clear rules for permitted use, conditional restrictions, and absolute contraindications.

Eligibility Scope

Menistin is approved for use in adults and older adults (geriatric population). While specific clinical trials are unavailable for patients with renal or hepatic impairment, post-marketing data suggests no dose adjustment is necessary in these populations.

Contraindications and Restrictions

Menistin is contraindicated in patients with a known hypersensitivity to the active substance or excipients, and those diagnosed with Phaeochromocytoma.

The medicine is not recommended for use in children and adolescents below 18 years due to insufficient data on safety and efficacy. Use during pregnancy or lactation should be avoided unless considered clearly necessary by a healthcare professional.

Certain pre-existing conditions require caution and careful monitoring, including bronchial asthma, a history of peptic ulceration, and severe hypotension. Patients with rare hereditary problems of galactose intolerance or malabsorption are also contraindicated due to excipient content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Menistin contains the active substance Betahistine, and its interaction profile is defined by its action as a histamine analogue and its specific metabolic pathway, as detailed in official regulatory documents.

Documented Pharmacological Interactions

Interacting Product Category Official Regulatory Classification Interaction Outcome Description
Histamine H1-receptor antagonists Pharmacodynamic Interaction Expected mutual attenuation of effect between the substances due to opposing pharmacological actions.
Monoamine Oxidase Inhibitors (MAOIs) Pharmacokinetic Interaction Inhibition of Betahistine's metabolism, resulting in increased systemic exposure. Caution is formally recommended for concomitant use.

Administration and Substance Interactions

Official regulatory documents note that taking the medicine during meals is an administration-timing condition that may mitigate common, mild gastrointestinal complaints. Regarding substances, case report observations documented in regulatory summaries include an interaction with ethanol and a specific observation of potentiation when co-administered with the Beta-2 agonist salbutamol. No specific, mandatory timing separation rules are documented between Menistin and other medicinal products besides the general note regarding meal administration.

Mechanism of Action

How Menistin Works: Mechanism of Action

Menistin functions as a dual reuptake inhibitor, primarily targeting the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET) . Its molecular interaction involves binding to these proteins on presynaptic nerve terminals, which prevents the rapid clearance (reuptake) of serotonin (5-HT) and norepinephrine (NE) from the synaptic cleft back into the neuron. This inhibitory action results in an immediate increase in the concentration and residence time of these neurotransmitters at the synapse.

This enhanced neurotransmitter availability modulates the activity of monoaminergic pathways across both the Central Nervous System (CNS) and the Peripheral Nervous System (PNS). The sustained alteration in synaptic levels triggers a slower, long-term adaptive change in postsynaptic receptor sensitivity, which is a key component of the overall mechanism. This cascade mediates a long-term adjustment in neural circuit activity, leading to an altered steady-state activity within the targeted pathways that influence neural circuits governing affective state and nociception.

Dosage and Administration Information

How to Use Menistin

Menistin is administered solely via the oral route using immediate-release tablets. These tablets are available in common strengths of 8 mg, 16 mg, and 24 mg to accommodate varied dosing needs. The established treatment protocol centers on a daily regimen where the total dose is administered in two or three divided doses throughout the day. The typical maintenance dose for adults ranges from 24 mg to 48 mg daily, and the maximum recommended daily intake is 48 mg.

For optimal administration, Menistin tablets should be taken preferably with meals or immediately following food. This timing is intended to help reduce the potential for mild gastric discomfort. The tablet must be swallowed whole with water and is not intended to be chewed or crushed. Some score lines on certain tablet strengths may exist only for ease of swallowing and should not be used to divide the dose into unequal parts.

In cases where a scheduled dose is missed, it is generally recommended to skip the missed dose entirely and resume the usual sequence with the next dose; doubling the dose is not recommended. Regarding specific populations, current clinical parameters indicate that no adjustment to the standard adult dose is necessary for older adults or those with renal or hepatic impairment. Menistin is not recommended for use in the paediatric population (under 18 years of age) due to insufficient clinical data. The duration of therapy can be long-term, potentially extending over several months.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Menistin

Evidence for Use in Managing Ménière's Disease

Research examined the patterns observed in patients with Ménière's disease, which is a condition characterized by fluctuating and episodic manifestations. Research has been conducted through Randomized Controlled Trials (RCTs), a core study design for evidence assessment. Systematic reviews analyzed data from these trials to explore how symptoms change over time. These studies were applied in populations of adults with a confirmed diagnosis of the condition.

The research examined several core outcomes related to physical discomfort, primarily measuring the frequency and severity of vertigo attacks using patient diaries. Studies also monitored changes in associated inner-ear symptoms, such as the perceived discomfort of tinnitus (ringing in the ear) and feelings of aural fullness. Findings from systematic reviews and pooled data contribute to understanding symptom patterns related to these episodic symptoms.

However, the certainty of evidence remains low regarding the research specifically exploring episodic symptom changes in the long term. Follow-up durations were limited in some of the pivotal trials, and the results apply only to the specific adult populations studied. Evidence quality varies across studies, and some regulatory evaluations have noted that findings were mixed regarding the observed symptom changes in high-quality controlled settings.

Study Focus: Vertigo Attack Frequency and Symptom Relief

This sub-section describes the specific tools used in research to monitor the changes observed in core symptoms. Investigators used detailed patient-reported outcomes describing perceived discomfort to track changes in the frequency and severity of vertigo. Research describes that these tools were relevant in evidence describing how symptoms are measured during phases of heightened symptom activity.


Evidence for Use in General Peripheral Vestibular Vertigo

Menistin was evaluated in research exploring the broader category of peripheral vestibular vertigo of various causes. This research includes large-scale observational studies conducted in routine clinical settings, as well as trials exploring responses in comparison to other comparator treatments. These studies were applied in research contexts involving fluctuating or unstable symptoms, examining patient-reported experiences related to systemic or functional imbalance.

Observational settings evaluating daily-life functioning contributed to the broader evidence landscape. Findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort and changes in functional measures, such as dizziness-related handicap scores. Pooled analyses of clinical trials data show patterns related to how symptoms evolved in the observed populations. Research also describes that studies monitored outcomes related to physical discomfort, including nausea and vomiting, that often accompany acute balance issues.

The data for this indication are still emerging from non-controlled settings, meaning that comparative evidence is lacking when attempting to isolate a specific symptomatic pattern from the condition’s natural course. Because many of the studies were observational, which do not include a placebo group, the evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly.


Long-Term Studies and Follow-Up Duration

Studies monitored responses over defined time intervals, used in research exploring how symptoms change over time. The longest trials conducted research focusing on episodes where symptoms become more noticeable, monitored patients for up to nine months to assess various outcomes.

While some observational reports provide insight into longer periods of use, long-term effects are not fully established and there is limited information for long-term outcomes supported by robust controlled research. The follow-up durations were limited in many initial trials, meaning that data on sustained management of symptoms beyond the intermediate term remains insufficient.


Evidence in Special Populations and Subgroups

Research was conducted primarily within the general adult population. As a result, data for certain groups are still emerging. For instance, limited information is available from studies that examined specific patient groups such as older adults with complex health profiles, or those with specific coexisting conditions that affect balance. Research provides context but not individual predictions for these special populations.


What the Scientific Literature Still Considers Uncertain

The evidence highlights what is known—and what is still uncertain—about Menistin. Key limitations noted in scientific literature include the variability across study methods and the reliance on subjective patient-reported outcomes. Results apply only to the populations studied, and findings were mixed for specific endpoints like the reduction in attack recurrence. The certainty remains low for certain findings, and comparative evidence is lacking in some areas; research is ongoing.

Key Studies & References

  1. Betahistine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Menistin (FAQ)


Q: Is Menistin the same type of drug as [Similar Drug Name]?

Menistin's active substance is classified in official regulatory documents as a histamine analogue and an antivertigo agent. This pharmacological classification indicates its focus on modulating certain receptors to help stabilize the inner ear's balance system. This helps define its specific type of action compared to other medicines.


Q: Does Menistin cause weight gain?

Weight gain is not listed as a Common, Uncommon, or Rare adverse reaction in the official regulatory safety documents for the medicine. Safety information focuses on adverse reactions that have been officially documented during clinical studies and post-marketing surveillance.


Q: Is it normal to feel tired after starting Menistin?

Tiredness or malaise is listed in some official safety documents as a Rare adverse effect. By contrast, Headache is listed as a Common side effect.


Q: Can Menistin affect how other common over-the-counter medicines work?

Yes, regulatory documents note that Menistin should be used with caution alongside certain other medicines. Specifically, official information states that Histamine H1-receptor antagonists (found in some common allergy or cold medications) may cause a mutual attenuation of effect when combined with Menistin. Regulatory documents emphasize the importance of communicating all medicines taken to a healthcare professional.


Q: Does Menistin cause headaches?

Yes, Headache is consistently listed in official prescribing information as a Common adverse reaction associated with this medicine. This means it is reported in between 1 out of 100 and 1 out of 10 people who use the drug.


Q: How long does it typically take before Menistin starts to work?

Official clinical information states that while some effects may be noticed quickly, significant improvement may sometimes only be observed after a couple of weeks of continuous treatment.


Q: Are there any specific foods or drinks that should be avoided with Menistin?

Regulatory guidance notes that taking the medicine with meals is described as being helpful to reduce the potential for common gastrointestinal discomfort. Official documents do not list specific foods or drinks that must be avoided, although the interaction summary does note a documented observation of an interaction with ethanol (alcohol).


Q: Is Menistin a controlled substance?

Based on official government drug classification databases (such as those maintained by the NIH and other national bodies), the active ingredient in Menistin is not currently designated or listed as a controlled substance.


Q: What happens if I forget to take my Menistin?

Official guidance states that if a scheduled dose is missed, patients should skip the missed dose entirely and simply resume the usual sequence with the next dose. Official guidance notes that the dose should not be doubled to make up for a missed one.


Q: Does Menistin interact with common herbal supplements?

While regulatory documents list specific pharmacological interactions, official bodies advise communicating the use of all substances, including herbal remedies and nutritional supplements. This is because interactions are a documented consideration in medical use.


Q: Can Menistin be taken with coffee or tea?

Official administration instructions recommend taking the medicine with meals or immediately following food to help reduce stomach upset. There are no specific or mandatory interaction warnings documented in regulatory summaries regarding the consumption of coffee or tea.


Q: What is the risk of a serious allergic reaction to Menistin?

The potential for severe Hypersensitivity reactions, such as Anaphylaxis, is officially documented among the post-marketing reports. However, the specific frequency of these serious adverse reactions is listed in official tables as 'Frequency Not Known'.


Q: Is there a warning about Menistin and driving?

Official patient information generally advises caution regarding driving or operating machinery if a person experiences specific side effects. This guidance is related to the potential for adverse reactions like dizziness, confusion, or convulsions, which are listed in official documents.


Q: Can Menistin change my mood?

Official safety data lists rare central nervous system adverse effects, including confusion and hallucinations. No common or frequent effects related to general mood changes or affective state are listed in the adverse reaction tables.


Q: Are there different brand names for Menistin?

Menistin is the specific brand name of a product that contains the active substance Betahistine. The active substance itself may be available worldwide under multiple different brand names, depending on the country or region.


Q: Is Menistin used to prevent something or to treat an existing condition?

The general purpose of the medicine is described in official documents as helping to manage severe balance disruption and persistent spinning sensations (vertigo). The medicine is utilized in adult patients to alleviate symptoms associated with an existing underlying condition.


Q: Are there any lifestyle changes recommended when taking Menistin?

Official documents focus primarily on drug administration and safety. Some patient information includes general suggestions for coping with side effects like stomach upset or headache.


Q: How long can a person stay on Menistin treatment?

Official prescribing information notes that therapy may be maintained for several months. Research studies have monitored patient responses over these defined time intervals.


How should Menistin be stored and disposed of?

How to Store and Dispose of Menistin?

The storage and handling of Menistin (Betahistine) tablets are strictly defined by regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30 C.
Protection Keep in the original container/blister pack and protect from moisture.
Safety Must be stored out of the sight and reach of children.

Disposal Instructions

To discard expired or unused medicine, follow official pharmaceutical waste guidelines. It is strictly required that Menistin not be thrown away via household waste or wastewater. Consult a pharmacist for instructions on how to properly dispose of medicines you no longer use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Menistin found in:

A-Z Index: